ClinicalTrials.gg
CompletedNCT05515432Updated Aug 21, 2023

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

A Phase 1 interventional study of Single oral dose of BAY3283142 IR (immediate release) tablet in Chronic Kidney Disease, Renal Impairment and Healthy Volunteers, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Enrollment
22nd of 32
45 · median 98
Started
2022
with 8 others
Phase 1
12 of 49
none open now
Registered
27th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 22nd largest by enrollment of the 32 interventional ones that give a count, is one of 9 that started in 2022, is one of 12 in phase 1, and was the 27th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 82 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD).

The kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. High blood pressure makes it more likely that the CKD gets worse.

The study treatment BAY3283142 is under development for treating CKD. It activates a protein called soluble guanylate cyclase (sGC) that generates cGMP - a molecule that relaxes blood vessels and is thought to have beneficial effects in CKD.

The participants do not benefit from this study. However, the study will provide information on how to use BAY3283142 in subsequent studies in people with CKD.

In previous studies, BAY3283142 was studied in participants with normal kidney function. As kidneys play a role in removal of drugs from the body, the degree of kidney function could influence the amount of BAY3283142 in the blood. Higher amounts may occur in people with reduced kidney function.

Therefore, the main purpose of this study is to learn how the study treatment BAY3283142 moves into, through, and out of the body in participants with mild to severe reduction of kidney function compared to matched participants with normal kidney function.

To answer this, the researchers will compare:

  • the (average) total level of BAY3283142 in the blood (also called AUC).
  • the (average) highest level of BAY3283142 in the blood (also called cmax) between the different groups. Participants will be in one of four groups based on how much their kidney function is reduced (mild, moderate, severe, end stage kidney disease) or in the control group.

All participants will take a single dose of BAY3283142 as tablet by mouth. Each participant will be in the study for approximately 4 weeks including an in-house stay of 6 days (with 5 overnight stays). In addition, a screening visit to the study site before the in-house stay is planned.

During the study, the study team will:

  • check vital signs
  • do physical examinations
  • take blood and urine samples
  • examine heart health using an electrocardiogram (ECG)
  • ask the participants questions about how they are feeling and what adverse events they are having

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

03

Conditions studied

  • Chronic Kidney Disease
  • Renal Impairment
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 82 years of age inclusive, at the time of signing the .
  • Normal kidney function or at different stages of renal impairment (mild to severe renal impairment, ESRD with hemodialysis or hemodiafiltration).
  • Race: White (Note: Clinical Data Interchange Standards Consortium [CDISC] definition of White: Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White [FDA]).
  • (BMI) within the range 18.0 and 35.0 kg/m\^2 (both inclusive).
  • Body weight equal or above 55 kg.
  • Male or female participants; women have to be of non- as defined in Section 10.4.1 (e.g., for at least 1 year, women with bilateral salpingectomy, women with bilateral ovariectomy, and women with hysterectomy).
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Men must agree to use a condom in sexual intercourse with female partner of childbearing potential and not to act as sperm donor for 10 days after dosing.
  • \<90 mL/min/1.73 m\^2 alculated by the CKD-EPI formula (eGFR must be repeated if screening period >10 days before dosing) 21 to 2 days prior to dosing and patients with ESRD on hemodialysis or hemodiafiltration.
  • Stable renal function (e.g., a serum creatinine value determined at least 3 months before the screening visit should not vary by more than 25% from the serum creatinine value determined at the screening visit).
  • eGFR ≥90 mL/min/1.73 m\^2 calculated by the CKD-EPI formula (eGFR must be repeated if screening period >10 days before dosing) 21 to 2 days prior to dosing.
  • Needs to be within the required matching age, gender, and body weight range.

Exclusion criteria

Exclusion Criteria:

  • Women of , pregnant or lactating women.
  • Medical disorder, condition, or history of such that would impair the participant's ability to participate or complete this study in the opinion of the investigator.
  • Known or suspected liver disorders (including Morbus Gilbert/Meulengracht) and bile secretion/flow (cholestasis).
  • Known to the study drugs (active substances or of the preparations).
  • Known severe allergies (e.g., allergies to more than 3 allergens, allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with ), urticaria, or significant non-allergic drug reactions.
  • Relevant acute diseases within the last 4 weeks prior to intake of study intervention.
  • Febrile illness within 2 weeks before intake of study intervention.
  • Known tendency for vasovagal reactions (e.g., after venipuncture) or history of syncope.
  • History of gastrointestinal surgery, with the exception of appendectomy unless it had been performed within the previous 12 months before screening.
  • Acute diarrhea or constipation within 14 days before intake of study intervention.
  • Diagnosed within the past 5 years with exception of completely resected basal cell cancer of the skin (excision >6 months before screening).
  • Planned intervention or surgery during the study which might impact the study objectives.
  • History of clinically relevant bleeding within the past 3 months.
  • Thrombotic disorder.
  • Use of systemic or topical medicines or substances which oppose the study objectives
  • Regular use of therapeutic or recreational drugs, e.g., carnitine products, anabolics, high dose vitamins (except for indicated medications for renally impaired).
  • Use of any herbal products or St. John's Wort within the last 14 days before intake of study intervention.
  • Excluded therapies (e.g., physiotherapy, acupuncture, etc.) within 1 week before intake of study intervention.
  • Change in chronic medications less than 2 weeks prior to dosing.
  • Participation in another clinical study during the preceding 3 months for multiple dose studies and 1 month for single dose studies (last visit of participant to previous study to first treatment of new study).
  • Exclusion periods from other studies or simultaneous participation in other clinical studies.
  • Previous treatment during this study (allowing previously treated participants to be re-included into the study may lead to bias).
  • Clinically relevant findings in the physical examination.
  • Positive results for virus surface antigen (HBsAg), virus antibodies (anti-HCV) (and with a positive polymerase chain reaction [PCR] result or increased liver transaminases or other signs of liver disease), antibodies 1+2/HIV p24 antigen (HIV-1/2 combi test).
  • Positive urine/mouth swab drug screening indicating drug abuse.
  • Positive alcohol breath test.
  • Special diets preventing the participants from eating the standard meals during the study.
  • Physical exercise within 96 h before admission the study site.
  • Regular daily consumption of more than 1 L of methylxanthine-containing food or beverages.
  • Consumption of methylxanthine-containing beverages or food (e.g., coffee, tea, cola drinks, and chocolate) within 48 h before intake of study intervention.
  • Smoking more than 10 cigarettes per day.
  • Regular daily consumption of more than 500 mL (male participants) or 250 mL (female participants) of usual beer or the equivalent quantity of approximately 20 g (male participants) or 10 g (female participants) of alcohol in another form.
  • Intake of foods or beverages containing alcohol within 96 h before intake of study intervention.
  • Donation of more than 100 mL of whole blood or plasma within 4 weeks or 500 mL whole blood within 3 months before intake of study intervention.
  • Plasmapheresis within 3 months prior to study intervention.
  • Suspicion of drug or alcohol abuse.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Mildly impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥60 - <90

    Participants with renal impairment

    Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

  • Experimental
    Moderately impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥30 - <60

    Participants with renal impairment

    Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

  • Experimental
    Severely impaired renal funtion: eGFR (mL/min/1.73 m^2) <30

    Participants with renal impairment

    Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

  • Experimental
    ESRD (end stage renal disease) on dialysis

    Participants with renal impairment

    Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

  • Experimental
    Normal renal function (control group): eGFR (mL/min/1.73 m^2) ≥90

    Age-, weight-, and gender-matched participants with normal renal function as control group

    Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

Interventions

  • DrugSingle oral dose of BAY3283142 IR (immediate release) tablet

    Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design

06

What researchers measure

Primary outcomes

  1. AUC of BAY3283142

    AUC(0-tlast) will be used as main parameters if AUC cannot be reliably determined in all participants

    Time frame: up to 0 - 96 hours post-dose

  2. AUCu of BAY3283142

    AUC(0-tlast)u will be used as main parameters if AUC cannot be reliably determined in all participants

    Time frame: up to 0 - 96 hours post-dose

  3. Cmax of BAY3283142

    Time frame: up to 0 - 96 hours post-dose

  4. Cmax,u of BAY3283142

    Time frame: up to 0 - 96 hours post-dose

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs) after intake of BAY3283142

    Time frame: up to 7 days post-dose

07

Study locations

1 site
  • CRS Clinical-Research-Services Kiel GmbH
    Kiel, Schleswig-Holstein 24105, Germany
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2023, 6 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Aug 25, 2022
StartActual
Aug 11, 2022
Primary completionActual
Mar 7, 2023
CompletionActual
Jun 6, 2023
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05515432
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Aug 11, 2022
Primary completion
Mar 7, 2023
Completion
Jun 6, 2023
Last update
Aug 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion